Evidence map›Paper›PMID 37940714›Full record

Observational studyAnnals of hematology2024

Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.

Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi and 16 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 1 country.

Noriharu Nakagawa *Department of Internal Medicine, Keiju Medical Center, Nanao, Japan.
Ken Ishiyama *Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan. ishiyama-knz@umin.ac.jp.ORCID http://orcid.org/0000-0002-6189-0620
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Shinagawa, Japan.
Satoru TakadaLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Tatsuki TomikawaDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Hiroshi HandaDepartment of Hematology, Gunma University Hospital, Maebashi, Japan.
Yuna KatsuokaDepartment of Hematology, Sendai Medical Center, National Hospital Organization, Sendai, Japan.
Daiki HiranoDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Nobuo SezakiDepartment of Hematology, Chugoku Central Hospital, Miyukichokamiiwanari, Japan.
Masahiko SumiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Shin FujisawaDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
Yasuhiro TaniguchiDepartment of Hematology and Rheumatology, Kindai University Hospital, Osakasayama, Japan.
Atsuko MugitaniDepartment of Hematology, Fuchu Hospital, Izumi, Japan.
Takuro YoshimuraDepartment of Hematology, Osaka City General Hospital, Osaka, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Ken TakaseDepartment of Hematology, Kyushu Medical Center, Fukuoka, Japan.
Youko SuehiroDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Tomohiro KajiguchiDepartment of Hematology and Oncology, Tosei General Hospital, Seto, Japan.
Tomoya MaedaDepartment of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Hidaka, Japan.
Masahide YamamotoDepartment of Hematology, Tokyo Medical and Dental University, Bunkyo, Japan.
Shigeki OhtakeDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Akira KatsumiDepartment of Hematology, National Center for Geriatrics and Gerontology, Obu, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Hospital, Osakasayama, Japan.
Yasushi MiyazakiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Kanazawa University Hospital · JPKindai University Hospital · JPChugoku Central Hospital · JPFuchu Hospital · JPGunma Saiseikai Maebashi Hospital · JPGunma University Hospital · JPNagano Red Cross Hospital · JPNagasaki University Hospital · JPNagoya University · JPNational Center for Geriatrics and Gerontology · JPNational Center for Global Health and Medicine · JPNational Hospital Organization · JPNational Hospital Organization Kyushu Cancer Center · JPNational Kyushu Medical Center · JPNTT Medical Center · JPOita Prefectural Hospital · JPOsaka City General Hospital · JPSaitama International Medical Center · JPSapporo Hokuyu Hospital · JPSendai Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndrome (MDS). However, whether bridging therapy (BRT) including azacitidine (AZA) and combination chemotherapy (CCT) prior to allo-SCT should be performed is unclear. We analyzed BRT and the outcomes of patients with myelodysplastic syndrome with excess blasts (MDS-EB) who were ≤ 70 years old at the time of registration for a prospective observational study to clarify the optimal allo-SCT strategy for high-risk MDS. A total of 371 patients were included in this study. Among 188 patients (50.7%) who were considered for allo-SCT, 141 underwent allo-SCT. Among the patients who underwent allo-SCT, 64 received AZA, 29 received CCT, and 26 underwent allo-SCT without BRT as the initial treatment. Multivariate analysis identified BRT as an independent factor influencing overall survival (AZA vs. without BRT, hazard ratio [HR] 3.33, P = 0.005; CCT vs. without BRT, HR 3.82, P = 0.003). In multivariate analysis, BRT was independently associated with progression-free survival (AZA vs. without BRT: HR, 2.23; P = 0.041; CCT vs. without BRT: HR, 2.94; P = 0.010). Transplant-eligible patients with MDS-EB should undergo allo-SCT when clinically acceptable, and upfront allo-SCT without BRT may be superior to AZA or CCT.

Indexed as

Hematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAgedAllograftsAzacitidineHumansRetrospective StudiesTransplantation, HomologousAzacitidineAllo-SCTAZABridging therapyMDS-EB

Identifiers

PMID37940714
OpenAlexW4388501703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.